Pharvaris N.V. (PHVS)
- Previous Close
20.56 - Open
20.62 - Bid 20.39 x 100
- Ask 21.12 x 100
- Day's Range
20.50 - 21.14 - 52 Week Range
15.00 - 33.00 - Volume
55,674 - Avg. Volume
91,340 - Market Cap (intraday)
1.124B - Beta (5Y Monthly) -3.10
- PE Ratio (TTM)
-- - EPS (TTM)
-2.85 - Earnings Date Aug 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.53
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
pharvaris.comRecent News: PHVS
View MorePerformance Overview: PHVS
Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHVS
View MoreValuation Measures
Market Cap
1.11B
Enterprise Value
731.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.08
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.79%
Return on Equity (ttm)
-45.05%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-114.1M
Diluted EPS (ttm)
-2.85
Balance Sheet and Cash Flow
Total Cash (mrq)
343.57M
Total Debt/Equity (mrq)
0.04%
Levered Free Cash Flow (ttm)
-55.19M
Research Analysis: PHVS
View MoreCompany Insights: PHVS
PHVS does not have Company Insights